A STAT investigation found artificial intelligence is driving Medicare Advantage denials to new heights, cutting off care for seniors.March 13, 2023Check out STAT+Sponsored By Mike Reddy for STAT Denied by AI: How Medicare Advantage plans use algorithms to cut off care for seniors in need A STAT investigation found artificial intelligence is driving Medicare Advantage denials to new heights, cutting off care for seniors. By Casey Ross and Bob Herman STAT+ | 102 hours of chaos: How SVB's collapse rattled the biotech industry The events of just a few days laid bare just how vulnerable the biotech and tech industries were to the financial turmoil at SVB. By Allison DeAngelis STAT+ | Veterans Health Administration will cover the newest Alzheimer's drug About 80% to 90% of veterans who clear coverage hurdles may be eligible for the treatment, according to Eisai. By Ed Silverman Adobe STAT+ | Buyer's remorse: How a Medicare Advantage business is strangling one of its first funders NaviHealth built a billion-dollar business scrutinizing Medicare Advantage care. Now, one of its first funders is throwing it under the bus. By Bob Herman and Casey Ross STAT+ | Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion The Seagan deal helps Pfizer, in need of new sources of revenue, by adding a lineup of cancer drugs called antibody-drug conjugates. By Adam Feuerstein STAT+ | French pharma Sanofi buys maker of diabetes treatment for $2.9 billion Sanofi said the acquisition will bolster the growth of its business targeting immune-mediated diseases and disease-modifying therapies. By Adam Feuerstein Neilson Barnard/Getty Images for New York Times STAT+ | Illumina has been ignoring its investors, but it can't ignore Carl Icahn Icahn argues Illumina is playing a losing hand with its actions related to the pursuit of its merger with Grail. By Matthew Herper Opinion: The second age of psychedelic therapies for mental health It will take some doing to make psychedelic therapies that use psilocybin and ketamine ready for prime time. By Greg Mayes More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments